OncoMatch/Clinical Trials/NCT07232524
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Is NCT07232524 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BL-M24D1 for head and neck squamous cell carcinoma.
Treatment: BL-M24D1 — This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic head and neck squamous cell carcinoma and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of chemotherapy ... within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: biotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of ... biotherapy ... within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: immunotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of ... immunotherapy within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: anthracycline
Exception: cumulative dose must not exceed 360 mg/m² during prior (neo)adjuvant anthracycline therapy
Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy
Lab requirements
Blood counts
Toxicities from prior antitumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block excluded; History of severe heart disease excluded
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block [excluded]; History of severe heart disease [excluded]; Organ function levels must meet the requirements; Coagulation function: International Normalized Ratio ≤1.5, and activated partial thromboplastin time ≤1.5 × ULN; Urine protein ≤2+ or ≤1000mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify